[1]刘贤丰,李子俊.恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(03):148-150.[doi:10.3969/j.issn.1006-1959.2019.03.048]
　LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Journal of Medical Information,2019,32(03):148-150.[doi:10.3969/j.issn.1006-1959.2019.03.048]
点击复制

恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年03期
页码:
148-150
栏目:
药物与临床
出版日期:
2019-02-01

文章信息/Info

Title:
Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma
文章编号:
1006-1959（2019）03-0148-03
作者:
刘贤丰; 李子俊
（江西省九江市第一人民医院胸心外科，江西 九江 332000）
Author(s):
LIU Xian-feng; LI Zi-jun
(Department of Thoracic and Cardiovascular Surgery,Jiujiang No.1 People's Hospital,Jiujiang 332000,Jiangxi,China)
关键词:
恩度; 培美曲塞; 顺铂; 肺腺癌
Keywords:
Endo; Pemetrexed; Cisplatin; Lung adenocarcinoma
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.03.048
文献标志码:
A
摘要:
目的 比较重组人血管内皮生成抑制素注射液（恩度）联合培美曲塞及顺铂化疗方案与单用培美曲塞联合顺铂方案治疗晚期肺腺癌的临床疗效。方法 选取81例经病理组织学或细胞学检查确诊的晚期肺腺癌初治患者，随机分为观察组（41例）和对照组（40例）。两组患者均给予培美曲塞+顺铂（PP方案）化疗，观察组在此基础上给予恩度治疗。评价两组近期临床疗效，采用生活质量卡氏（KBS）评分评价患者治疗前后生存质量及治疗期间不良反应，计算中位进展时间。结果 观察组近期有效率为46.15%，高于对照组的37.50%，差异有统计学意义（P＜0.05）；观察组中位肿瘤进展时间为8.65个月，高于对照组的5.31个月，差异有统计学意义（P＜0.05）；两组生活质量评分及不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 恩度联合培美曲塞+顺铂治疗晚期肺腺癌可提高近期临床疗效，延长肿瘤进展时间，改善生活质量，且不增加不良反应，具有较好的临床疗效及安全性。
Abstract:
Objective To compare the clinical efficacy of recombinant human endostatin injection (Endo) combined with pemetrexed and cisplatin chemotherapy with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma.Methods 81 patients with advanced lung adenocarcinoma diagnosed by histopathology or cytology were randomly divided into observation group (41 cases) and control group (40 cases). Both groups were given pemetrexed + cisplatin (PP regimen) chemotherapy, and the observation group was given en-degree treatment on this basis. The short-term clinical efficacy of the two groups was evaluated. The quality of life (KBS) score was used to evaluate the quality of life before and after treatment and the adverse reactions during the treatment. The median progression time was calculated.Results The effective rate of the observation group was 46.15%, which was higher than that of the control group 37.50%, the difference was statistically significant (P<0.05).The median tumor progression time of the observation group was 8.65 months, which was higher than the control group of 5.31 months,the difference was statistically significant (P<0.05).There was no significant difference in the quality of life scores and adverse reactions between the two groups(P>0.05).Conclusion Endo combined with pemetrexed plus cisplatin in the treatment of advanced lung adenocarcinoma can improve the short-term clinical efficacy, prolong the tumor progression time, improve the quality of life, and does not increase adverse reactions, and has good clinical efficacy and safety.

参考文献/References:


[1]Torre LA,Siegel RL,Ahmedin J.Lung Cancer Statistics[J].Adv Exp Med Biol,2016(893):1-19.
[2]Theegarten D,Hager T.Pathology of lung cancer[J].Der Radiologe,2016,56(9):777.
[3]Lin JJ,Cardarella S,Lydon CA,et al.Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer,2016,11(4):556-565.
[4]Yanagita K,Nagashio R,Ryuge S,et al.Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma[J].2015,16(17):7959-7965.
[5]赵变锋.恩度联合奥沙利铂、卡培他滨治疗晚期大肠癌的疗效研究[J].首都食品与医药,2017,24(8):80-81.
[6]刘丹,陈剑.重组人血管内皮抑素治疗非小细胞肺癌的研究进展[J].癌症进展,2018,14(2):128-129.
[7]Hu W,Jian F,Nie J,et al.Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer[J].Medicine,2016,95(28):e4183.
[8]薛国亮,毕经旺,张聪.培美曲塞、顺铂联合重组人血管内皮抑制素治疗肺腺癌[J].中国基层医药,2013,20(23):3538-3540.
[9]冯丽华,陈毅德,高应勤,等.重组人血管内皮抑制素联合培美曲塞和顺铂方案治疗晚期肺腺癌的临床观察[J].肿瘤研究与临床,2015,27(8):518-521.
[10]卢筠,谢强,陈群,等.重组人血管内皮抑素联合顺铂胸腔内注射治疗肺腺癌恶性胸腔积液的临床研究[J].临床肺科杂志,2016,21(9):1664-1667.

相似文献/References:

[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,31(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
　PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Journal of Medical Information,2018,31(03):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
[2]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
　SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Journal of Medical Information,2021,34(03):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
[3]雷希君,罗利琼.腔内灌注治疗恶性胸腔积液的研究现状[J].医学信息,2024,37(03):184.[doi:10.3969/j.issn.1006-1959.2024.03.039]
　LEI Xi-jun,LUO Li-qiong.Research Status of Intracavitary Perfusion in the Treatment of Malignant Pleural Effusion[J].Journal of Medical Information,2024,37(03):184.[doi:10.3969/j.issn.1006-1959.2024.03.039]

更新日期/Last Update: 2019-02-25